In yesterday’s Wall Street session, Verve Therapeutics Inc (NASDAQ:VERV) shares traded at $10.77, up 15.93% from the previous session.
10 analysts cover Verve Therapeutics Inc (NASDAQ:VERV), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $75.00 and a low of $22.00, we find $55.00. Given the previous closing price of $9.29, this indicates a potential upside of 492.03 percent. VERV stock price is now -12.59% away from the 50-day moving average and -33.67% away from the 200-day moving average. The market capitalization of the company currently stands at $686.59M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 2 analysts and a buy rating from 8. Brokers who have rated the stock have averaged $46.44 as their price target over the next twelve months.
With the price target of $29, Canaccord Genuity recently initiated with Buy rating for Verve Therapeutics Inc (NASDAQ: VERV).
In other news, Bellinger Andrew, CSO & CMO sold 865 shares of the company’s stock on Dec 01. The stock was sold for $19,852 at an average price of $22.95. Upon completion of the transaction, the CSO & CMO now directly owns 6,629 shares in the company, valued at $71394.33. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 29, Chief Financial Officer Dorval Allison sold 554 shares of the business’s stock. A total of $12,243 was realized by selling the stock at an average price of $22.10. This leaves the insider owning 2,186 shares of the company worth $23543.22. Insiders disposed of 1,419 shares of company stock worth roughly $15282.63 over the past 1 year. A total of 32.75% of the company’s stock is owned by insiders.
On Tuesday morning Verve Therapeutics Inc (NASDAQ: VERV) stock kicked off with the opening price of $9.99. During the past 12 months, Verve Therapeutics Inc has had a low of $8.22 and a high of $27.93. As of last week, the company has a debt-to-equity ratio of 0.17, a current ratio of 14.41, and a quick ratio of 14.41. The fifty day moving average price for VERV is $12.32 and a two-hundred day moving average price translates $16.24 for the stock.
The latest earnings results from Verve Therapeutics Inc (NASDAQ: VERV) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.72, beating analysts’ expectations of -$0.92 by 0.2. This compares to -$0.79 EPS in the same period last year. The net profit margin was -2528.21% and return on equity was -38.24% for VERV. The company reported revenue of $3.12 million for the quarter, compared to $0.93 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 235.52 percent. For the current quarter, analysts expect VERV to generate $1.17M in revenue.
Verve Therapeutics Inc(VERV) Company Profile
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
